Patient Support and Advocacy

Hypoparathyroidism and ADH1 Support in Australia

The Australian patient organisation for people living with hypoparathyroidism and Autosomal Dominant Hypocalcemia Type 1 (ADH1). We connect patients and families, share trusted information, and advocate for access to better treatments in Australia.

Free to join  |  Donations tax‑deductible  |  ACNC Registered  |  DGR Endorsed

400–1,100 Australians Estimated Living with ADH1
41% Present with Severe Symptoms
75% of Published ADH1 Cases on Standard Therapy Had Complications

“Living with hypoparathyroidism or ADH1 often means managing symptoms other people can’t see, like fatigue, brain fog and muscle cramps, alongside the constant work of keeping calcium levels stable. New treatments are arriving: one is already registered in Australia but not yet subsidised, and others are moving through trials and regulators. That’s why CaSR Patient Support exists: to make sure Australian patients aren’t left behind as these treatments become available.”

Nicholas Love Chairman, CaSR Patient Support
Our Mission

How We Make a Difference

CaSR Patient Support unites patients, researchers, clinicians, and policymakers to advocate for better treatment for hypoparathyroidism and ADH1.

Patient Resources

Guides, fact sheets, and support for patients and families living with hypoparathyroidism and ADH1.

Learn More

Research & Progress

Keeping patients and families informed about research into hypoparathyroidism and ADH1, including clinical trials they may be able to join.

CaSR Patient Support has received grant funding from BridgeBio Pharma, Inc. See our funding disclosure.

Learn More

Campaigns & Advocacy

Advocating for timely access to new treatments in Australia, engaging government and representing patients’ needs to regulators and decision‑makers.

Learn More

Your Donation Is Tax‑Deductible

CaSR Patient Support is an ACNC‑registered charity endorsed as a Deductible Gift Recipient (DGR). All donations are tax‑deductible.

Donate Now
Make an Impact

Support Our Journey

Your tax-deductible donation funds patient support, trusted information, awareness and advocacy for treatment access. Together, we can advocate for access to better treatments for hypoparathyroidism and ADH1.

$3,655 raisedof $90,000 in 2026-27

Donations received in the 2026-27 financial year. Grants are listed separately under Our funding and are not included.

Donate Now

Donations are tax‑deductible • DGR Endorsed

Our Funding

Industry support

  • BridgeBio Pharma, Inc.

    In 2026 BridgeBio Pharma, Inc. provided CaSR Patient Support with a grant of AUD 15,000 for our Patient Advocacy & Engagement Initiative (October to December 2026). The grant supports patient meetups, patient education and advocacy, and patient engagement across Australia.

    Type: grant (industry support) | Amount: AUD 15,000 | Period: October to December 2026

CaSR Patient Support keeps full editorial, educational and program independence. BridgeBio has no input into, or approval of, our advocacy positions, educational content or patient communications. Our patient education materials are reviewed by our Medical Advisory Board. Funding is not contingent on promoting any medicine or product.

Government grants

  • Australian Government, Department of Social Services

    A 2025-26 Volunteer Grant of $2,750 supporting our volunteers (September 2026 to September 2027). Funded by the Australian Government Department of Social Services.

    Type: grant (government) | Amount: AUD 2,750 | Period: September 2026 to September 2027

In-kind support

  • Google Ad Grants: CaSR Patient Support is a participant in the Google Ad Grants program. Ad Grants offers eligible organizations access to up to $10,000 per month in Search ads shown on Google.com to help them connect to people searching for their mission, raise awareness, attract donors, and recruit new volunteers.Since April 2026
  • Microsoft Azure: Cloud computing credit for nonprofits.May 2026 to May 2027
  • Canva for Nonprofits: Free design software.Since June 2026

Grants and in-kind support are not donations and are not counted in the donations total.

Our Governance Committee

Led by Experts, Driven by Patients

Our committee brings together clinical expertise, financial governance, and lived patient experience.

Nicholas Love
Chairman, Public Officer
MAcc, BCom (ANU), CPA
Prof Roderick Clifton-Bligh
Head of Medical Advisory Board
BSc(Med), MBBS(Hons), FRACP, PhD, FFSc(RCPA)
Catherine Love
Committee Member, Acting Treasurer
BA, DipSec
Margaret Love
Secretary, Education Coordinator
RN, Midwife, BN, MAdultEd

Get Research Updates Delivered

Join patients and supporters receiving news on treatment access, advocacy and clinical trials for hypoparathyroidism and ADH1.

Your Support

Small Amounts. Real Impact.

We are entirely volunteer‑run, so donations fund the work itself: patient support, patient resources and ongoing advocacy.

Tax‑deductible ACNC registered
Advocacy

Patient submissions to government decision‑makers

Resources

Plain‑language patient information resources

Access

TGA evaluation and PBS listing advocacy campaigns

Stay Connected

Receive the most important research updates, advocacy news, and event invitations directly in your inbox.